Zika Virus Transmission Unlikely at High Altitudes: Revised CDC Travel Notice


Morbidity and Mortality Weekly Report (MMWR)

Early Release
March 11, 2016 / 65

Revision to CDC's Zika Travel Notices: Minimal Likelihood for Mosquito-Borne Zika Virus Transmission at Elevations Above 2,000 Meters

Since May 2015, when Zika virus, a flavivirus transmitted primarily by Aedes aegypti mosquitoes, was reported in Brazil, the virus has rapidly spread across the Region of the Americas and the Caribbean. The association between maternal Zika virus infection and adverse fetal and reproductive outcomes, including microcephaly, prompted CDC to issue a Level 2 alert travel notice for the 37 countries and U.S. territories (at the national and territorial level) that have reported recent Zika virus transmission as of March 11, 2016. In addition to mosquito bite precautions for all travelers, CDC advises that pregnant women postpone travel to affected countries and U.S. territories. Within a nation’s borders, ecologic characteristics, which determine the distribution of mosquito vectors, can vary considerably. CDC conducted a spatial analysis, focusing on the probability of occurrence of Ae. aegypti, to support the demarcation for subnational travel alerts. Based on results of this analysis, travel that is limited to elevations higher than 2,000 m (6,562 ft) above sea level is considered to have minimal (approximately 1%) likelihood for mosquito-borne Zika virus transmission, even within countries reporting active transmission. Women who are pregnant should avoid travel to elevations <2,000 m in countries with active Zika virus transmission.

Zika virus is a flavivirus primarily transmitted by Aedes species mosquitoes. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. Currently, outbreaks of Zika virus disease are occurring in many countries and U.S. territories, and as of March 11, 2016, CDC had issued 37 Level 2 travel notices for areas with ongoing Zika virus transmission. Currently, when laboratory-confirmed local Zika virus transmission is first reported, travel notices are issued for the entire country or U.S. territory. Establishing more precisely defined areas of Zika virus risk in a country or U.S. territory is complicated by incomplete surveillance data on the disease and the presence of the mosquito vector.

In an effort to develop more precise guidance for travelers, CDC evaluated whether subnational travel notices could be based on an ecologic indicator of the probable absence of the predominant Zika virus mosquito vector, Ae. aegypti. Within a nation’s borders, ecologic factors, such as temperature, precipitation, vegetation, and human population density, that define suitable habitats for Aedes species vary. Where habitat is unsuitable, the mosquito vector is likely to be absent, and risk for mosquito-borne Zika virus transmission is likely to be negligible.

The first step in developing subnational travel notices required identification of a single, easily quantifiable ecologic variable that could be used as a substitute for the likely absence of Ae. aegypti. Of the many ecologic factors affecting habitat suitability and Ae. aegypti survival as a vector for Zika virus, temperature has been the most frequently investigated and rigorously quantified; however, temperature varies widely and is difficult to predict locally and over the long term. Historically, elevation has served as a reasonable proxy for temperature. Because it is static and relatively easy to measure, elevation was selected for further investigation. Previous reports from various global regions suggest that Ae. aegypti is present, but rare, between elevations of 1,700–2,100 m. Therefore, this analysis was restricted to countries and U.S. territories that have 1) ongoing Zika virus transmission and 2) areas with high elevations (starting at >1,500 m). Sixteen countries, including Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, and Venezuela have areas which fit these criteria. No U.S. territories had elevations at that level.

Spatial analyses were conducted using multiple data sets: global data on predicted probabilities of the presence of Ae. aegypti based on 20,000 observed occurrences during 1960–2014; remotely sensed data on human population density; global geographic data on human dengue cases during 1960–2012; and a digital elevation model; zonal statistics were used to relate the data sets. Within each of the 16 countries, the area of land suitable for Ae. aegypti, and the human population counts within each area were quantified. The quantification was done in 100-m elevation segments for elevations between 0 m and 2,500 m. Across all 16 countries, at elevations >2,000 m, Ae. aegypti was predicted to be largely absent. Because of sparse current geographic data on Zika virus cases, cases of dengue, another vector-borne viral disease spread primarily by Ae. aegypti, were examined as a proxy for Zika cases. Only 1.1% (28/2,682) of dengue cases in the global data set were reported to have occurred at elevations >2,000 m in the 16 countries.

A CDC Zika virus travel notice is currently applied to an entire country or U.S. territory when transmission is confirmed by a local public health authority. However, Ae. aegypti might not be uniformly present because of differences in ecologic suitability. Recent advances in scientific modeling have allowed for more precision in geospatial analyses. CDC applied these approaches to previously published and rigorously evaluated data to determine if more precise guidance to travelers and persons living in affected regions could be established. The results from the spatial analyses of 16 countries with ongoing Zika virus transmission and elevation points >1,500 m indicate that Ae. aegypti is unlikely to be found at elevations >2,000 m because of unsuitable ecologic factors, including but not limited to, low temperatures. Consequently, at elevations above 2,000 m, the risk for mosquito-borne exposure to Zika virus is considered to be minimal. These findings support revising the Zika travel notice to reflect enhanced geographic precision regarding the likelihood of Zika virus presence at certain elevations.

With this revision, CDC recommends that women who are pregnant should postpone travel to areas that are at elevations <2,000 m above sea level in countries and U.S. territories with ongoing Zika virus transmission. Because Zika virus is primarily spread by mosquitoes, CDC recommends that travelers protect themselves from mosquito bites. Travel that is entirely limited to elevations >2,000 m is considered to pose minimal likelihood for mosquito-borne Zika virus transmission. As additional geographic data specific to Zika virus cases in relation to elevation become available, these recommendations will be reviewed and revised as needed.

Centers for Disease Control and Prevention
www.cdc.gov

The above message comes from CDC, who is solely responsible for its content.

Comments

Post a Comment

Cool

Popular posts from this blog

10 EARLY PREGNANCY SYMPTOMS WHICH APPEAR BEFORE MISSING A PERIOD

Many women experience the first pregnancy symptoms days before missing a period as a result of the shift in the hormones, which causes certain changes in the body. The first pregnancy symptoms can occur up to a week before a sufficient number of pregnancy hormones starts to circulate in the body to give a positive result on the pregnancy test. Here are the earliest symptoms of pregnancy, which appear before a missed period. Pregnancy Symptoms Cramping Cramping is one of the earliest symptoms of pregnancy. The cramps can be noticed when your embryo implants into your uterus. This sign can be easily mistaken for menstrual cramps. Fatigue Increased levels of progesterone can make you feel exhausted. Fatigue is usually experienced as early as a week after ovulation. After you ovulate, the levels of progesterone rise, regardless of being pregnant or not. However, if you are not pregnant your progesterone levels will soon decrease. After ovulation, if you start feeling tired, and if t...
Read more

First Birth Control For Men, An Injection To The Groin, Will Be Available Soon

The use of contraceptives has been largely associated with women, but birth control for men might soon be available for use after Indian scientists announced that they have successfully completed clinical trials on the world’s first male birth control injection. The Indian Council for Medical Research said that the “product is ready,” and has a 97.3% success rate with no side effects, according to a report from the Hindustan Times. The contraceptive works via an injection to the vas deferens, the sperm-containing tube near the testicles. It contains a polymer called Steryene Maleic Anhydride, which was developed in the 1970s to inhibit sperm production. According to the report, the contraceptive will be effective for 13 years. VG Somani, the Drug Controller General of India, estimates approval of the drug to take around six months, minimum. “It’s the first in the world from India so we have to be extra careful about approval. We are looking at all aspects, especiall...
Read more

Novartis sickle-cell drug gets U.S. FDA approval

By John Miller and Carl O’Donnell (Reuters) - Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. The drug will be priced between $84,852 and $113,136 per year for most patients, who will be infused by a healthcare provider with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. The Food and Drug Administration’s approval came nearly two months ahead of its due date for a decision in January. Novartis has forecast that the drug’s annual sales will top $1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid. The dru...
Read more